Research and experimental development on natural sciences and engineering
ONCOSYNE AS
Revenue 2024
NOK 4.4m
Operating profit
NOK −2.0m
Equity
NOK 10.8m
Incorporated
2020
Employees
6
Share capital
NOK 1.1m
Roles
Regnskapsfører
Styrets lederPeter Andreas Wold Eide
StyremedlemJanne Merethe Nestvold
StyremedlemJohn Edvard Karlsrud
StyremedlemSvenn Widerberg
StyremedlemBjørn Olav Bakka
Shareholders
| Name | Stake | Shares | Year |
|---|---|---|---|
| NORSKE OMVEIER AS | 31.1% | 350000.000000 | 2025 |
| KAARSTAD SMIER AS | 31.1% | 350000.000000 | 2025 |
| WIBO CONSULTING AS | 8.8% | 98753.000000 | 2025 |
| DAEDALUS AS | 6.3% | 71395.000000 | 2025 |
| STARTUPLAB FOUNDERS FUND IV AS | 5.9% | 66752.000000 | 2025 |
| MILLIMEDIA AS | 4.2% | 46917.000000 | 2025 |
| FORTRESS FUND 1 AS | 3.4% | 38350.000000 | 2025 |
| FARVATN VENTURE AS | 2.5% | 28222.000000 | 2025 |
| SVARTHØI HOLDING AS | 1.8% | 20734.000000 | 2025 |
| JO STRØMGREN | 1.8% | 20734.000000 | 2025 |
| JALCO CONSULTING AS | 1.7% | 18814.000000 | 2025 |
| MIKKEL BOVIM BUGGE | 0.9% | 10368.000000 | 2025 |
| LILLE PERSILLE FAMILIEBARNEHAGE AS | 0.3% | 3762.000000 | 2025 |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.